Sangamo Therapeutics Inc (SGMO)
0.5197
+0.02
(+3.32%)
USD |
NASDAQ |
Apr 26, 16:00
0.5329
+0.01
(+2.54%)
After-Hours: 20:00
Sangamo Therapeutics Revenue (TTM): 176.23M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 176.23M |
| September 30, 2023 | 201.42M |
| June 30, 2023 | 218.48M |
| March 31, 2023 | 241.02M |
| December 31, 2022 | 111.30M |
| September 30, 2022 | 112.06M |
| June 30, 2022 | 114.16M |
| March 31, 2022 | 112.65M |
| December 31, 2021 | 110.70M |
| September 30, 2021 | 108.52M |
| June 30, 2021 | 137.72M |
| March 31, 2021 | 131.40M |
| December 31, 2020 | 118.19M |
| September 30, 2020 | 147.24M |
| June 30, 2020 | 111.44M |
| March 31, 2020 | 107.43M |
| December 31, 2019 | 102.43M |
| September 30, 2019 | 74.41M |
| June 30, 2019 | 76.02M |
| March 31, 2019 | 79.89M |
| December 31, 2018 | 84.45M |
| September 30, 2018 | 70.69M |
| June 30, 2018 | 58.94M |
| March 31, 2018 | 45.78M |
| December 31, 2017 | 36.57M |
| Date | Value |
|---|---|
| September 30, 2017 | 32.41M |
| June 30, 2017 | 23.42M |
| March 31, 2017 | 18.87M |
| December 31, 2016 | 19.39M |
| September 30, 2016 | 19.59M |
| June 30, 2016 | 25.33M |
| March 31, 2016 | 29.99M |
| December 31, 2015 | 39.54M |
| September 30, 2015 | 45.37M |
| June 30, 2015 | 49.22M |
| March 31, 2015 | 51.24M |
| December 31, 2014 | 45.87M |
| September 30, 2014 | 37.79M |
| June 30, 2014 | 31.08M |
| March 31, 2014 | 27.63M |
| December 31, 2013 | 24.13M |
| September 30, 2013 | 26.20M |
| June 30, 2013 | 25.40M |
| March 31, 2013 | 23.04M |
| December 31, 2012 | 21.66M |
| September 30, 2012 | 17.47M |
| June 30, 2012 | 14.42M |
| March 31, 2012 | 11.36M |
| December 31, 2011 | 10.32M |
| September 30, 2011 | 10.26M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
74.41M
Minimum
Sep 2019
241.02M
Maximum
Mar 2023
132.25M
Average
112.65M
Median
Mar 2022
Revenue (TTM) Benchmarks
| AIM ImmunoTech Inc | 0.202M |
| Perspective Therapeutics Inc | 0.00 |
| Protalix BioTherapeutics Inc | 65.49M |
| Electromed Inc | 51.69M |
| Armata Pharmaceuticals Inc | -- |